Retrospective and Prospective single arm, observational study to evaluate efficacy and safety of NIF in the treatment of ventricular tachycardia and ventricular fibrillation. The information registration of the target population will be collected with the hospital HIS system or LIS system.
Subjects enrolled in the retrospective study may be enrolled in a prospective study if the study drug is re-used, but in the end only the most-registered case of the subject would be collected. The recommended treatment plan for this study is from the usage and dosage of NIF. The clinician can make appropriate adjustments to the specific usage and dosage according to the patient's condition. Load dose: Adults usually use 0.3mg/kg each time, under continuous ECG monitoring, the injection should be completed within 5 minutes, and the maximum dose should not exceed 0.5 mg/kg. Maintenance dose: After load injection, the adult routine dose is 0.4 mg/kg/h under continuous ECG monitoring. The dosage could be appropriately increased or decreased according to the patient's reaction, but the maximum dose should not exceed 0.8 mg/kg/h.
Study Type
OBSERVATIONAL
Enrollment
2,000
Treatment is not limited. Patients who have used or will use Nifekalant hydrochloride.
Peking University First Hospital
Beijing, Beijing Municipality, China
RECRUITINGThe rate of termination / prevention of ventricular tachycardia / ventricular fibrillation attack and relapse.
The efficiency during the treatment and observation periods, including the rate of termination / prevention of ventricular tachycardia / ventricular fibrillation attack and relapse.
Time frame: From the beginning of the administration to 48 hours after the end of the administration.
Number of Participants with adverse events
Number of Participants with Tdp, ventricular tachycardia or ventricular fibrillation.
Time frame: From the beginning of the administration to 48 hours after the end of the administration.
Heart rate
The subjects' heart rate will be recorded and the abnormalities will be analyzed.
Time frame: 3 days before the beginning of the administration to 48 hours after the end of the administration.
The survival rate
The 30 days survival rate.
Time frame: 30 days after the end of administration.
Blood pressure
Both systolic and diastolic pressures will be assessed during the study period.
Time frame: 3 days before the beginning of the administration to 48 hours after the end of the administration.
Respiratory rate
The respiratory status of all subjects will be recorded the incidence of abnormalities will be calculated.
Time frame: 3 days before the beginning of the administration to 48 hours after the end of the administration.
Body temperature
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
The subjects' temperatures will be recorded and the abnormalities will be analyzed.
Time frame: 3 days before the beginning of the administration to 48 hours after the end of the administration.